Literature DB >> 21142587

Short communication: transplacental nucleoside analogue exposure and mitochondrial parameters in HIV-uninfected children.

Susan B Brogly1, Salvatore DiMauro, Russell B Van Dyke, Paige L Williams, Ali Naini, Daniel E Libutti, Julia Choi, Michelle Chung, Mariana Gerschenson.   

Abstract

Transplacental nucleoside analogue exposure can affect infant mitochondrial DNA (mtDNA). We evaluated mitochondria in peripheral blood mononuclear cells of children with and without clinical signs of mitochondrial dysfunction (MD) and antiretroviral (ARV) exposure. We previously identified 20 children with signs of MD (cases) among 1037 HIV-uninfected children born to HIV-infected women. We measured mtDNA copies/cell and oxidative phosphorylation (OXPHOS) NADH dehydrogenase (complex I) and cytochrome c oxidase (complex IV) protein levels and enzyme activities, determined mtDNA haplogroups and deletions in 18 of 20 cases with stored samples and in sex- and age-matched HIV-uninfected children, both ARV exposed and unexposed, (1) within 18 months of birth and (2) at the time of presentation of signs of MD. In specimens drawn within 18 months of birth, mtDNA levels were higher and OXPHOS protein levels and enzyme activities lower in cases than controls. In contrast, at the time of MD presentation, cases and ARV-exposed controls had lower mtDNA levels, 214 and 215 copies/cell, respectively, than ARV-unexposed controls, 254 copies/cell. OXPHOS protein levels and enzyme activities were lower in cases than exposed controls, and higher in cases than unexposed controls, except for complex IV activity, which was higher in cases. Haplotype H was less frequent among cases (6%) than controls (31%). No deletions were found. The long-term significance of these small but potentially important alterations should continue to be studied as these children enter adolescence and adulthood.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21142587      PMCID: PMC3159117          DOI: 10.1089/aid.2010.0204

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  17 in total

1.  Sequencing strategy of mitochondrial HV1 and HV2 DNA with length heteroplasmy.

Authors:  E M Rasmussen; E Sørensen; B Eriksen; H J Larsen; N Morling
Journal:  Forensic Sci Int       Date:  2002-10-09       Impact factor: 2.395

2.  Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals.

Authors:  Mariana Gerschenson; Bruce Shiramizu; Daniel E LiButti; Cecilia M Shikuma
Journal:  Antivir Ther       Date:  2005

3.  Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy status.

Authors:  Cecilia M Shikuma; Mariana Gerschenson; Dominic Chow; Daniel E Libutti; John H Willis; James Murray; Roderick A Capaldi; Michael Marusich
Journal:  AIDS Res Hum Retroviruses       Date:  2008-10       Impact factor: 2.205

4.  Zidovudine administration during pregnancy and mitochondrial disease in the offspring.

Authors:  Pier-Angelo Tovo; Nadia Chiapello; Clara Gabiano; Massimo Zeviani; Marco Spada
Journal:  Antivir Ther       Date:  2005

5.  mtDNA and the origin of Caucasians: identification of ancient Caucasian-specific haplogroups, one of which is prone to a recurrent somatic duplication in the D-loop region.

Authors:  A Torroni; M T Lott; M F Cabell; Y S Chen; L Lavergne; D C Wallace
Journal:  Am J Hum Genet       Date:  1994-10       Impact factor: 11.025

6.  Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.

Authors:  Ellen R Cooper; Manhattan Charurat; Lynne Mofenson; I Celine Hanson; Jane Pitt; Clemente Diaz; Karen Hayani; Edward Handelsman; Vincent Smeriglio; Rodney Hoff; William Blattner
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-15       Impact factor: 3.731

7.  Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy.

Authors:  Bruce Shiramizu; Kelsey M Shikuma; Lori Kamemoto; Mariana Gerschenson; Guliz Erdem; Marcello Pinti; Andrea Cossarizza; Cecilia Shikuma
Journal:  J Acquir Immune Defic Syndr       Date:  2003-04-01       Impact factor: 3.731

8.  Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort.

Authors:  Béatrice Barret; Marc Tardieu; Pierre Rustin; Catherine Lacroix; Brigitte Chabrol; Isabelle Desguerre; Catherine Dollfus; Marie-Jeanne Mayaux; Stéphane Blanche
Journal:  AIDS       Date:  2003-08-15       Impact factor: 4.177

9.  Perinatal exposure to antiretroviral therapy is associated with increased blood mitochondrial DNA levels and decreased mitochondrial gene expression in infants.

Authors:  Hélène C F Côté; Janet Raboud; Ari Bitnun; Ariane Alimenti; Deborah M Money; Evelyn Maan; Adriana Costei; Izabelle Gadawski; Christina Diong; Stanley Read; Sandy Shen; P Richard Harrigan; David R Burdge; Susan M King; John C Forbes
Journal:  J Infect Dis       Date:  2008-09-15       Impact factor: 5.226

10.  Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy.

Authors:  Grace A McComsey; Minhee Kang; Allison C Ross; Dirk Lebrecht; Elizabeth Livingston; Ann Melvin; Jane Hitti; Susan E Cohn; Ulrich A Walker
Journal:  HIV Clin Trials       Date:  2008 Mar-Apr
View more
  20 in total

1.  Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals.

Authors:  Katherine M Knapp; Susan B Brogly; Daniel G Muenz; Hans M L Spiegel; Daniel H Conway; Gwendolyn B Scott; Jeffrey T Talbot; David E Shapiro; Jennifer S Read
Journal:  Pediatr Infect Dis J       Date:  2012-02       Impact factor: 2.129

2.  Epidermal nerve fiber density, oxidative stress, and mitochondrial haplogroups in HIV-infected Thais initiating therapy.

Authors:  Todd Hulgan; Rebecca T Levinson; Mariana Gerschenson; Nittaya Phanuphak; Jintanat Ananworanich; Nipat Teeratakulpisarm; Tanate Jadwattanakul; Daniel E LiButti; Heidi Fink; Justin C McArthur; Gigi J Ebenezer; Peter Hauer; Deborah Murdock; Cecilia M Shikuma; David C Samuels
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177

3.  Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment.

Authors:  Floris Fauchet; Jean-Marc Treluyer; Silvia M Illamola; Claire Pressiat; Gabrielle Lui; Elodie Valade; Laurent Mandelbrot; Jerome Lechedanec; Sandrine Delmas; Stéphane Blanche; Josiane Warszawski; Saik Urien; Roland Tubiana; Déborah Hirt
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

4.  Elevated Blood Mitochondrial DNA in Early Life Among Uninfected Children Exposed to Human Immunodeficiency Virus and Combination Antiretroviral Therapy in utero.

Authors:  Abhinav Ajaykumar; Mayanne Zhu; Fatima Kakkar; Jason Brophy; Ari Bitnun; Ariane Alimenti; Hugo Soudeyns; Sara Saberi; Arianne Y K Albert; Deborah M Money; Hélène C F Côté
Journal:  J Infect Dis       Date:  2021-02-24       Impact factor: 5.226

5.  Short communication: The relationship between mitochondrial dysfunction and insulin resistance in HIV-infected children receiving antiretroviral therapy.

Authors:  Tanvi S Sharma; Denise L Jacobson; Lynn Anderson; Mariana Gerschenson; Russell B Van Dyke; Elizabeth J McFarland; Tracie L Miller
Journal:  AIDS Res Hum Retroviruses       Date:  2013-09       Impact factor: 2.205

Review 6.  HIV-exposed uninfected children: a growing population with a vulnerable immune system?

Authors:  L Afran; M Garcia Knight; E Nduati; B C Urban; R S Heyderman; S L Rowland-Jones
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

Review 7.  The other genome: a systematic review of studies of mitochondrial DNA haplogroups and outcomes of HIV infection and antiretroviral therapy.

Authors:  Anna B Hart; David C Samuels; Todd Hulgan
Journal:  AIDS Rev       Date:  2013 Oct-Dec       Impact factor: 2.500

8.  Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.

Authors:  Grace A McComsey; Eric S Daar; MaryAnn O'Riordan; Ann C Collier; Lisa Kosmiski; Jorge L Santana; Carl J Fichtenbaum; Heidi Fink; Paul E Sax; Daniel E Libutti; Mariana Gerschenson
Journal:  J Infect Dis       Date:  2012-11-29       Impact factor: 5.226

9.  Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants.

Authors:  Patricia A Sirois; Yanling Huo; Paige L Williams; Kathleen Malee; Patricia A Garvie; Betsy Kammerer; Kenneth Rich; Russell B Van Dyke; Molly L Nozyce
Journal:  Pediatr Infect Dis J       Date:  2013-06       Impact factor: 2.129

10.  Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.

Authors:  Steven E Lipshultz; Lynn M Anderson; Tracie L Miller; Mariana Gerschenson; Kristen E Stevenson; Donna S Neuberg; Vivian I Franco; Daniel E LiButti; Lewis B Silverman; Lynda M Vrooman; Stephen E Sallan
Journal:  Cancer       Date:  2016-01-13       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.